Clene Inc. (CLNN) SEC filings

CLNNNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 1/30

$3.92−0.08 (-2.00%)

Close on Nov 13, 2026Market cap $50.37MP/E –Yield –

SEC filings

40 of Clene's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Quarterly report	10-Q	Sep 30, 2026	Nov 4, 2026	SEC EDGAR
Current report	8-K	Nov 4, 2026	Nov 4, 2026	SEC EDGAR
Current report	8-K	Oct 15, 2026	Oct 20, 2026	SEC EDGAR
Current report	8-K	Oct 19, 2026	Oct 19, 2026	SEC EDGAR
Current report	8-K	Sep 15, 2026	Sep 16, 2026	SEC EDGAR
Current report	8-K	Aug 14, 2026	Aug 14, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 14, 2026	SEC EDGAR
Current report	8-K	Aug 10, 2026	Aug 10, 2026	SEC EDGAR
Current report	8-K	May 18, 2026	May 22, 2026	SEC EDGAR
Current report	8-K	May 11, 2026	May 14, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 14, 2026	SEC EDGAR
Current report	8-K	May 5, 2026	May 5, 2026	SEC EDGAR
Current report	8-K	May 4, 2026	May 4, 2026	SEC EDGAR
Proxy statement	DEF 14A	Dec 31, 2025	Apr 10, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Mar 17, 2026	SEC EDGAR
Current report	8-K	Mar 13, 2026	Mar 17, 2026	SEC EDGAR
Current report	8-K	Mar 12, 2026	Mar 12, 2026	SEC EDGAR
Current report	8-K	Feb 24, 2026	Feb 24, 2026	SEC EDGAR
Current report	8-K	Jan 8, 2026	Jan 13, 2026	SEC EDGAR
Current report	8-K	Jan 12, 2026	Jan 12, 2026	SEC EDGAR
Current report	8-K	Dec 3, 2025	Dec 3, 2025	SEC EDGAR
Current report	8-K	Dec 3, 2025	Dec 3, 2025	SEC EDGAR
Current report	8-K	Nov 13, 2025	Nov 13, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 13, 2025	SEC EDGAR
Current report	8-K	Oct 17, 2025	Oct 17, 2025	SEC EDGAR
Current report	8-K	Oct 14, 2025	Oct 14, 2025	SEC EDGAR
Current report	8-K	Sep 25, 2025	Sep 25, 2025	SEC EDGAR
Current report	8-K	Sep 5, 2025	Sep 5, 2025	SEC EDGAR
Current report	8-K	Aug 13, 2025	Aug 14, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 14, 2025	SEC EDGAR
Current report	8-K	Jul 3, 2025	Jul 3, 2025	SEC EDGAR
Current report	8-K	Jun 30, 2025	Jun 30, 2025	SEC EDGAR
Current report	8-K	Jun 17, 2025	Jun 17, 2025	SEC EDGAR
Current report	8-K	May 21, 2025	May 23, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	May 7, 2025	SEC EDGAR
Current report	8-K	May 6, 2025	May 7, 2025	SEC EDGAR
Current report	8-K	Apr 28, 2025	Apr 28, 2025	SEC EDGAR
Proxy statement	DEF 14A	Dec 31, 2024	Apr 8, 2025	SEC EDGAR
Current report	8-K	Apr 8, 2025	Apr 8, 2025	SEC EDGAR
Current report	8-K	Mar 26, 2025	Mar 27, 2025	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Clene's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-20 reverse split on Jul 11, 2024
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CLNN.

Compare: CLNN vs SER · CLNN vs ABVC · CLNN vs LEXX · CLNN vs IXHL · CLNN vs VCNX

Revenue growth11.2% · median -31.5%

Operating margin-8928.6% · median -3545.2%

Net margin-11271.4% · median -3543.0%

Company	Revenue	Growth
VCNX	$601.00K	+5.4%
CLNN	$238.00K	+11.2%
LEXX	$194.00K	-68.5%
SER	–	–
ABVC	–	–
IXHL	–	–

Company

Next earnings (est.): Mar 11, 2027, before open
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 79
Held by institutions: 24.8%
Auditor: Deloitte & Touche LLP
SEC CIK: 1822791

Advertisement
300 × 250

See a number that looks wrong?